Home Expanding the windows of opportunity beyond oncology for conjugate-based therapeutics
2023 | November / December 2023

Expanding the windows of opportunity beyond oncology for conjugate-based therapeutics

by cyb2025
P. Dieterich
ADC design toolkit
Antibody drug conjugates (ADC’s)
Antibody oligo conjugates (AOC’s)
Bioconjugates
bioconjugation
Oligo-conjugates
oligonucleotides

PETRA DIETERICH
Franchise Leader and Head of Scientific Leaders, Abzena

ABSTRACT

Antibody drug conjugates (ADC’s) are nascent modalities that open the therapeutic window to allow high potent molecules to target specific tumour cell receptors. ADC’s are already established as the standard of care in breast cancer with Enhertu, Kadcyla and Trodelvy accounting for $4.1 Bn of the total $4.7 Bn ADC revenues in 2022. A further 460 novel ADC’s are in development for lung, gastric, ovarian and colorectal cancer alone with potential to superceed existing small molecule chemotherapies and capture a market of more than $140 bn.
Over the last 20 years, drug developers have invented a phlefora of technologies to supercharge antibodies via the conjugation with small molecules and this has created a toolbox of techniques to allow us to conjugate proteins and peptides with a variety of different molecules. Coupling of proteins with oligonucleotides allows us to create oligo drug conjugates which offer treatment solutions outside of the oncology space with potential in personalised medicines as well as high frequency conditions such as neurodenerative and respiratory diseases.
In this article we explore how we can use our toolbox of techniques to open more windows to hitherto untreated diseases.

Introduction
Bioconjugation is expanding the repertoire of drug modalities available to address previously intractable targets with precision and positively impact both rare and common life-limiting diseases. The most widely known examples are antibody drug conjugates (ADCs) and while the field is still relatively nascent, this modality has become increasingly prevalent in cancer treatments in the last 2 decades.

ABOUT THE AUTHOR

Petra Dieterich has 30 years’ experience of drug development in the Pharmaceutical industry with a focus on supporting CMC activities. She has held leadership positions in Project Management, Technical Operations and Business Development. Working in the CRO and CDMO environment she has led projects for customers across the globe, helping them to achieve their goals in clinical trials and low volume commercial manufacture. Petra holds a D.Phil in synthetic organic chemistry and an MBA from Imperial College London.

Latest issue

November /December 2025

View Issue

Archive

For an even more in-depth scientific analysis, consult the archive

Chemistry Today - Archive
Go to archive

Content from magazine

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores.
View all content

Most popular

@2026 - All Right Reserved.

Login